58
Participants
Start Date
July 3, 2017
Primary Completion Date
November 20, 2017
Study Completion Date
November 20, 2017
Faster-acting insulin aspart
In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
Insulin aspart
In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
Novo Nordisk Investigational Site, Neuss
Lead Sponsor
Novo Nordisk A/S
INDUSTRY